Market Overview

The China generic drug market size was USD 64.1 Billion in 2024 and is projected to reach USD 154.6 Billion by 2033, growing at a CAGR of 10.27% between 2025 and 2033. Market expansion is driven by patent expirations on brand-name drugs, government initiatives promoting generics, cost-containment measures, and rising chronic disease prevalence. The China Generic Drug Market report offers deep insights into growth trends and market dynamics.

Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

China Generic Drug Market Key Takeaways

  • Current Market Size: USD 64.1 Billion in 2024
  • CAGR: 10.27% (2025-2033)
  • Forecast Period: 2025-2033
  • Patent expirations on brand-name drugs facilitate market entry for generic drug manufacturers.
  • Government support includes centralized drug procurement programs encouraging generics use in public hospitals.
  • Price caps and insurance promotion increase generic drugs’ adoption.
  • Chronic diseases like diabetes (with 13% prevalence among adults in 2021) drive demand for affordable long-term medication.

Sample Request Link: https://www.imarcgroup.com/China-Generic-Drug-Market/requestsample

Market Growth Factors

Patent expiration for a prescription drug allows generic drug companies with bioequivalent formulations to produce the drug at lower prices (the "patent cliff"). Generic drugs can take market share away from brand-name drugs when they are sold at lower prices than brand-name drugs so that they are the cheaper alternative. The Chinese government supports the use of generic drugs to increase access and lower cost. The use of generic drugs is encouraged in public hospitals via a centralized drug procurement (CDP) program to increase market competition. The NMPA also approved simplified standards for generic drug registration with standards equivalent to the originator drug and programs such as the Quality Consistency Evaluation (QCE) to further improve domestic generic drug quality and improve consumer confidence.

Due to rising cost of healthcare in China, healthcare providers and the government have implemented cost-containment measures to curtail these costs. Generic drugs are the most cost-effective choice as they cost less than their counterparts. China has a new national bulk-buy program that deals directly with medications, lowering prices and encouraging more generics in hospitals. The government has also imposed price controls on certain essential drugs, making generics a more attractive option for providers and patients. Additionally, insurers and providers are encouraging generics as a lower-cost substitute for branded drugs.

Chronic diseases like diabetes, hypertension, cardiovascular diseases, and cancer are highly popular, require long-term medication, and also create stable demand for low-priced drugs. For instance, China populated 1079960800 adults during 2021 and 13% of the people had diabetes, estimating 140869600. The use of generic medicines can reduce costs by providing chronic disease medications, which can benefit health systems. Furthermore, medical progress such as improvements in diagnosis may lead to earlier detection of chronic disease and increased long-term medication use. This trend shows a constant demand and a promising future for the market of generic drugs.

Market Segmentation

Therapy Area Insights

  • Central Nervous System: Includes analysis of generics used for neurological conditions, indicating expanding applications.
  • Cardiovascular: Covers generic drugs for heart-related diseases, an essential segment given chronic disease prevalence.
  • Dermatology: Encompasses generics targeting skin-related conditions.
  • Genitourinary/Hormonal: Analyzes generic medications in this category.
  • Respiratory: Includes generic drugs for respiratory diseases.
  • Rheumatology: Covers generics for autoimmune and joint disorders.
  • Diabetes: Focuses on generic treatments for diabetes management.
  • Oncology: Includes generic cancer treatments.
  • Others: Covers remaining therapy areas.

Drug Delivery Insights

  • Oral: The primary drug delivery mode covered by generic drugs.
  • Injectables: Analysis of injectable generic medications.
  • Dermal/Topical: Includes generics applied to the skin.
  • Inhalers: Covers inhalable generic drug forms.

Distribution Channel Insights

  • Retail Pharmacy: Analysis of generic drug sales through retail outlets.
  • Hospital Pharmacy: Includes generics distributed in hospitals.
  • Online Pharmacy: Covers online sales channels for generics.

Request Customization:

https://www.imarcgroup.com/request?type=report&id=23430&flag=E 

Regional Insights

The report covers major regions including North China, East China, South Central China, Southwest China, Northwest China, and Northeast China. However, the source does not specify the dominant region or provide explicit market shares or growth rates.

Recent Developments & News

In October 2023, the China National Medical Products Administration (NMPA) introduced a regulatory requirement mandating that Abbreviated New Drug Applications (ANDAs) for generic drugs without reference listed drugs must demonstrate clinical value. This change aims to ensure generic drugs are both clinically and chemically effective.

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302